Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 455

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 455
---
/2036                  
 5/19/2036                  
 5/19/2036                  |     |                 |

280

| Patent Family                              |     | Description                                                                                                  |     | Application/      
 Publication/      
 Patent Number     |     | Filing Date |     | Issue Date/     
 Status          |     | Earliest        
 Expected        
 Expiration Date |     | Type of Patent  
 Protection      |
| Modified mRNA for Multicell Transformation |     | Next generation cancer vaccine using mRNA encoding a bacterial antigen to prime anti-cancer immune responses |     | PCT/US2021/031204 
 (WO 2021/226413)  |     | 5/7/2021    |     | Nationalized in 
 CN, JP, CA, IN, 
 AU, EP, KR To   
 be filed in HK  |     | 5/7/2041        |     |                 |
| Exosome Delivery of Cancer Therapeutics    |     | Production and use of exosome preparations to systemically deliver pDNA and or mRNA to                       |     | US 18/055,724     
 (US 2023-0183690) |     | 11/15/2022  |     | Published/      
 pending         |     |                 |     | Composition/use |

Employees and Human Capital Resources As of December 31, 2024, TuHURA had 19 full-time employees and no part-time employees. Of these employees, 15 were engaged in research and development activities. The majority of TuHURA’s employees are based in Tampa, Florida. None of TuHURA’s employees are represented by labor unions or covered by collective bargaining agreements. TuHURA considers its relationship with its employees to be good. TuHURA’s human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating TuHURA’s existing and new employees, advisors and consultants. The principal purposes of TuHURA’s equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of the company by motivating such individuals to perform to the best of their abilities and achieve its objectives. Government Regulation and Product Approval Therapeutic products are subject to rigorous regulation by the FDA and other governmental agency regulations in the United States and in foreign countries. Noncompliance with applicable requirements can result in import detentions, fines, civil monetary penalties, injunctions